Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Archives of Dermatological Research
Published in:

Open Access 01-10-2024 | Acne Inversa | CONSENSUS ARTICLE

Improving hidradenitis suppurativa management: consensus statements from physicians and patients’ perspectives

Authors: Angelo Valerio Marzano, Cristina Magnoni, Giuseppe Micali, Angelina De Magnis, Giuseppina Pintori, Simone Fiorini, Valentina Simonella, Linda Bastioli, Francesca Nappi, Giovanni Pappagallo, Francesca Prignano

Published in: Archives of Dermatological Research | Issue 8/2024

Login to get access

Abstract

Hidradenitis suppurativa (HS) is a frequent chronic inflammatory skin condition primarily affecting areas rich in apocrine sweat glands, presenting with comedones, papules, nodules, and abscesses, as well as tunnels and hypertrophic scarring. Despite its prevalence and impact on quality of life, the pathogenesis of HS remains incompletely understood. Notably, its diagnosis often suffers from delays and misidentification, therefore an improved education for healthcare providers is mandatory. Moreover, HS is frequently associated with systemic comorbidities and a multidisciplinary approach is suggested for its management. Recognizing these challenges, a group of Italian HS experts and patients convened to develop consensus guidelines via the Nominal Group Technique. Through iterative meetings and remote collaboration, they identified key areas for improvement and formulated consensus statements to guide healthcare providers in delivering optimal care. This collaborative effort highlights the importance of standardized approaches and interdisciplinary collaboration in managing HS effectively.
Appendix
Available only for authorised users
Literature
1.
Zouboulis CC et al (2020) What causes hidradenitis suppurativa?–15 years after. Exp Dermatol 29(12):1154–1170PubMedCrossRef
2.
Antonelli F et al (2023) Clinical features and response to treatment in elderly subjects affected by hidradenitis suppurativa: a cohort study. J Clin Med 12(24):7754PubMedPubMedCentralCrossRef
3.
Frew JW et al (2021) A systematic review of promising therapeutic targets in hidradenitis suppurativa: a critical evaluation of mechanistic and clinical relevance. J Invest Dermatol 141(2):316–324PubMedCrossRef
4.
Marzano AV et al (2022) Whole-exome sequencing in 10 unrelated patients with syndromic hidradenitis suppurativa: a preliminary step for a genotype-phenotype correlation. Dermatology 238(5):860–869PubMedCrossRef
5.
6.
Saunte DML, Jemec GBE (2017) Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318(20):2019–2032PubMedCrossRef
7.
8.
Johnston LA et al (2022) Practical guidelines for managing patients with hidradenitis suppurativa: an update. J Cutan Med Surg 26(2):2S-24SPubMedCrossRef
9.
Saunte DM et al (2015) Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol 173(6):1546–1549PubMedCrossRef
10.
Chadha SA et al (2023) Assessing unmet needs in patients with hidradenitis suppurativa. Arch Dermatol Res 315(9):2555–2560PubMedCrossRef
11.
Daoud M et al (2023) Overview and comparison of the clinical scores in hidradenitis suppurativa: a real-life clinical data. Front Med (Lausanne) 10:1145152PubMedCrossRef
12.
Pescitelli L, Ricceri F, Prignano F (2018) Hidradenitis suppurativa and associated diseases. G Ital Dermatol Venereol 153(3):8–17PubMed
13.
14.
Saito-Sasaki N, Sawada Y (2023) The development of systemic inflammatory diseases in hidradenitis suppurativa. Diagn (Basel) 13(3):502
15.
16.
Alter M (2024) Hidradenitis suppurativa. Dermatologie (Heidelb)
17.
Bettoli V et al (2016) Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: evidence from the national Italian registry. Br J Dermatol 174(1):195–197PubMedCrossRef
18.
19.
Gallagher M et al (1993) The nominal group technique: a research tool for general practice? Fam Pract 10(1):76–81PubMedCrossRef
20.
McMillan SS, King M, Tully MP (2016) How to use the nominal group and delphi techniques. Int J Clin Pharm 38(3):655–662PubMedPubMedCentral
21.
Gustafson DH, Shukla RK, Delbecq A, Walster GW (1973) A comparative study of differences in subjective likelihood estimates made by individuals, interacting groups, delphi groups, and nominal groups. Organ Behav Hum Perform 9:280CrossRef
22.
Rowe G, Wright G (2001) Expert opinions in forecasting: role of the delphi technique. Princ Forecast 30:125CrossRef
23.
24.
Gallego D, Bueno S (2014) Exploring the application of the delphi method as a forecasting tool in information systems and technologies research. Technol Anal Strateg Manag 26:987CrossRef
25.
Kaplan MF (1987) The influencing process in group decision making. Group processes. Sage Publications, Inc, Thousand oaks
26.
Snyder CL, Chen SX, Porter ML (2023) Obstacles to Early diagnosis and treatment of hidradenitis suppurativa: current perspectives on improving clinical management. Clin Cosmet Investig Dermatol 16:1833–1841PubMedPubMedCentralCrossRef
27.
Chiricozzi A et al (2018) The hidradenitis suppurativa (HS) “multidisciplinary unit”: a rationale and practical proposal for an organised clinical approach. Eur J Dermatol 28(2):274–275PubMedCrossRef
28.
Chiricozzi A, Micali G, Veraldi S (2019) The patient journey: a voyage from diagnosis to hidradenitis suppurativa multidisciplinary unit. J Eur Acad Dermatol Venereol 33(6):15–20PubMedCrossRef
29.
van der Zee HH, Jemec GB (2015) New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes. J Am Acad Dermatol 73(5):S23–S26PubMedCrossRef
30.
Scala E et al (2021) Hidradenitis suppurativa: where we are and where we are going. Cells 10(8):1013CrossRef
31.
Margesson LJ, Danby FW (2014) Hidradenitis suppurativa. Best Pract Res Clin Obstet Gynaecol 28(7):1013–1027PubMedCrossRef
32.
Zouboulis CC et al (2017) Development and validation of the International hidradenitis suppurativa severity score system (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 177(5):1401–1409PubMedCrossRef
33.
Tzellos T et al (2023) Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. J Eur Acad Dermatol Venereol 37(2):395–401PubMedCrossRef
34.
Timila Touhouche A et al (2020) Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice. Int J Womens Dermatol 6(3):164–168PubMedPubMedCentralCrossRef
35.
Otten M et al (2023) Measuring quality of life in hidradenitis suppurativa: development and validation of a disease-specific patient-reported outcome measure for practice and research. Acta Derm Venereol 103:adv00859PubMedCrossRef
36.
Matusiak L, Bieniek A, Szepietowski JC (2010) Psychophysical aspects of hidradenitis suppurativa. Acta Derm Venereol 90(3):264–268PubMedCrossRef
37.
Rymaszewska JE et al (2023) Satisfaction with life and coping strategies among patients with hidradenitis suppurativa: a cross-sectional study. J Clin Med 12(8):2775CrossRef
38.
Bettoli V et al (2016) The hidradenitis suppurativa patient journey in Italy: current status, unmet needs and opportunities. J Eur Acad Dermatol Venereol 30(11):1965–1970PubMedCrossRef
39.
Kashetsky N et al (2022) Patient experiences with hidradenitis suppurativa: the hidradenitis patient experience survey. Clin Exp Dermatol 47(1):72–79PubMedCrossRef
40.
Tang B et al (2023) Complications of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. Int Wound J 20(4):1253–1261PubMedCrossRef
41.
Rompel R, Petres J (2000) Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 26(7):638–643PubMedCrossRef
42.
Lacarrubba F et al (2018) Role of the imaging techniques in the diagnosis and staging of hidradenitis suppurativa. G Ital Dermatol Venereol 153(3):20–25PubMed
43.
Srisajjakul S, Prapaisilp P, Bangchokdee S (2022) Magnetic resonance imaging of hidradenitis suppurativa: a focus on the anoperineal location. Korean J Radiol 23(8):785–793PubMedPubMedCentralCrossRef
44.
45.
Mazeika E, Jariene V, Valiukeviciene S (2021) Medical infrared thermography as hidradenitis suppurativa diagnostic tool: literature review. Postepy Dermatol Alergol 38(2):32–35PubMedPubMedCentralCrossRef
46.
Nazary M et al (2011) Pathogenesis and pharmacotherapy of Hidradenitis suppurativa. Eur J Pharmacol 672(1–3):1–8PubMedCrossRef
47.
48.
Diaz MJ et al (2023) Hidradenitis suppurativa: molecular etiology, pathophysiology, and management—a systematic review. Curr Issues Mol Biol 45(5):4400–4415PubMedPubMedCentralCrossRef
49.
Zouboulis CC et al (2015) European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 29(4):619–644PubMedCrossRef
50.
Blum FR, DeBarmore BM, Sayed CJ (2023) Hidradenitis suppurativa in older adults. JAMA Dermatol 159(2):216–219PubMedCrossRef
51.
Liy-Wong C et al (2021) Hidradenitis suppurativa in the pediatric population: an international, multicenter, retrospective, cross-sectional study of 481 pediatric patients. JAMA Dermatol 157(4):385–391PubMedCrossRef
52.
Rosi E et al (2022) Hidradenitis suppurativa: the influence of gender, the importance of trigger factors and the implications for patient habits. Biomedicines 10(11):2973PubMedPubMedCentralCrossRef
53.
Chu CB, Yang CC, Tsai SJ (2021) Hidradenitis suppurativa: disease pathophysiology and sex hormones. Chin J Physiol 64(6):257–265PubMedCrossRef
54.
55.
Lyons AB et al (2020) Evaluation of hidradenitis suppurativa disease course during pregnancy and postpartum. JAMA Dermatol 156(6):681–685PubMedCrossRef
56.
Tugnoli S et al (2020) Anger, emotional fragility, self-esteem, and psychiatric comorbidity in patients with hidradenitis suppurativa/acne inversa. J Clin Psychol Med Settings 27(3):527–540PubMedCrossRef
57.
58.
Wlodarek K et al (2020) Psychosocial burden of hidradenitis suppurativa patients’ partners. J Eur Acad Dermatol Venereol 34(8):1822–1827PubMedCrossRef
59.
Narla S, Lyons AB, Hamzavi IH (2020) The most recent advances in understanding and managing hidradenitis suppurativa. F1000Res 9:1049CrossRef
60.
Zouboulis CC, Chernyshov PV (2021) Hidradenitis suppurativa-specific, patient-reported outcome measures. J Eur Acad Dermatol Venereol 35(7):1420–1421PubMedCrossRef
61.
Kirby JS et al (2020) The hidradenitis suppurativa quality of life (HiSQOL) score: development and validation of a measure for clinical trials. Br J Dermatol 183(2):340–348PubMedCrossRef
62.
Zouboulis CC (2021) Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument. Br J Dermatol 184(6):1203–1204PubMedCrossRef
63.
Maronese CA et al (2024) Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev Clin Immunol 20(5):525–545PubMedCrossRef
64.
Kimball AB et al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375(5):422–434PubMedCrossRef
65.
Kimball AB et al (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 401(10378):747–761PubMedCrossRef
66.
67.
Garg A et al (2020) Evaluating patients’ unmet needs in hidradenitis suppurativa: results from the global survey of impact and healthcare needs (VOICE) Project. J Am Acad Dermatol 82(2):366–376PubMedCrossRef
68.
Alikhan A et al (2019) North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part i: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol 81(1):76–90PubMedPubMedCentralCrossRef
69.
Kirby JS et al (2020) A narrative review of the definition of ‘flare’ in hidradenitis suppurativa. Br J Dermatol 182(1):24–28PubMedCrossRef
70.
71.
Rathod U et al (2023) Hidradenitis suppurativa: a literature review comparing current therapeutic modalities. Cureus 15(8):e43695PubMedPubMedCentral
72.
Bechara FG et al (2021) Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg 156(11):1001–1009PubMedCrossRef
73.
Kromann CB et al (2014) Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study. Br J Dermatol 171(4):819–824PubMedCrossRef
74.
Sartorius K et al (2009) Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 161(4):831–839PubMedCrossRef
75.
Acharya P, Mathur M (2020) Hidradenitis suppurativa and smoking: a systematic review and meta-analysis. J Am Acad Dermatol 82(4):1006–1011PubMedCrossRef
76.
Deilhes F et al (2020) Profile of smoking dependency in hidradenitis suppurativa patients and smoking cessation outcomes. J Eur Acad Dermatol Venereol 34(12):e790–e791PubMedCrossRef
Metadata
Title
Improving hidradenitis suppurativa management: consensus statements from physicians and patients’ perspectives
Authors
Angelo Valerio Marzano
Cristina Magnoni
Giuseppe Micali
Angelina De Magnis
Giuseppina Pintori
Simone Fiorini
Valentina Simonella
Linda Bastioli
Francesca Nappi
Giovanni Pappagallo
Francesca Prignano
Publication date
01-10-2024
Publisher
Springer Berlin Heidelberg
Keyword
Acne Inversa
Published in
Archives of Dermatological Research / Issue 8/2024
Print ISSN: 0340-3696
Electronic ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-024-03316-2

Other articles of this Issue 8/2024

Archives of Dermatological Research 8/2024 Go to the issue

Research Letter

Strategies to improve access to photoprotection and sun safety for diverse socioeconomic communities

Research Letter

Burow’s triangle as a flipped island pedicle flap to approximate wide linear closures

ORIGINAL PAPER

The impact of lipidome on five inflammatory skin diseases: a Mendelian randomization study

Original Paper

Investigation of the in-vitro lethal effect of spilanthol on demodex and finding the most effective dose

Research Letter

Hepatitis C and its treatment in patients with psoriasis: a propensity-matched case-control study

Review

The brain-skin axis in vitiligo